menu
    • menu

    Company profile for Oncolytics Biotech

    NEW Drugs in Dev: 3
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Oncolytics BiotechCanada Flag
    Country
    Country
    Canada
    Address
    Address
    210, 1167 Kensington Crescent NW Calgary, Alberta T2N 1X7
    Telephone
    Telephone
    (403) 670-7377
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oncolyticsbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncolytics-biotech-inc./
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oncolytics Shows Durable Responses in RAS-Mutant CRC Cancer
    Oncolytics Shows Durable Responses in RAS-Mutant CRC Cancer

    04 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/04/3286772/0/en/oncolytics-biotech-reports-durable-responses-in-second-line-ras-mutant-mss-colorectal-cancer.html

    GLOBENEWSWIRE
    04 May 2026
    Share Share
    Oncolytics Aligns With FDA on Planned Pivotal Anal Cancer Study
    Oncolytics Aligns With FDA on Planned Pivotal Anal Cancer Study

    27 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7212981

    FIRSTWORD PHARMA
    27 Apr 2026
    Share Share
    Oncolytics Schedules FDA Meeting on Pelareorep in Anal Cancer
    Oncolytics Schedules FDA Meeting on Pelareorep in Anal Cancer

    06 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/06/3268468/0/en/Oncolytics-Biotech-Announces-Type-C-FDA-Meeting-to-Discuss-Single-arm-Registrational-Pathway-for-Pelareorep-in-Anal-Cancer.html

    GLOBENEWSWIRE
    06 Apr 2026
    Share Share
    Oncolytics Biotech Completes Domicile Change to the United States
    Oncolytics Biotech Completes Domicile Change to the United States

    01 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/01/3266672/0/en/Oncolytics-Biotech-Completes-Domicile-Change-to-the-United-States.html

    GLOBENEWSWIRE
    01 Apr 2026
    Share Share
    Oncolytics Unveils Pelareorep Immune-Priming Data at AACR 2026
    Oncolytics Unveils Pelareorep Immune-Priming Data at AACR 2026

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3259093/0/en/Oncolytics-Biotech-to-Present-New-Mechanistic-and-Translational-Data-Supporting-Pelareorep-as-an-Immune-Priming-Backbone-at-AACR-2026.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    Oncolytics Biotech Launches Randomized Colorectal Cancer Study
    Oncolytics Biotech Launches Randomized Colorectal Cancer Study

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247443/0/en/Oncolytics-Biotech-Launches-Randomized-Colorectal-Cancer-Study.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search